Literature DB >> 19215021

Interaction of PDGFRA promoter haplotypes and maternal environmental exposures in the risk of spina bifida.

Mascha Toepoel1, Regine P M Steegers-Theunissen, N Joop Ouborg, Barbara Franke, Angela M González-Zuloeta Ladd, Paul H L J Joosten, Everardus J J van Zoelen.   

Abstract

BACKGROUND: Neural tube defects are multifactorial malformations involving both environmental exposures, such as maternal nutrition, and genetic factors. Aberrant expression of the platelet-derived growth factor alpha-receptor (PDGFRA) gene has been implicated in neural-tube-defect etiology in both mice and humans.
METHODS: We investigated possible interactions between the PDGFRA promoter haplotype of mother and child, as well as maternal glucose, myo-inositol, and zinc levels, in relation to spina bifida offspring. Distributions were determined of the PDGFRA promoter haplotypes H1 and H2 in a Dutch cohort, consisting of 88 spina bifida children with 56 of their mothers, and 74 control children with 72 of their mothers, as well as maternal plasma glucose, myo-inositol, and red blood cell zinc concentrations.
RESULTS: A significantly higher frequency of H1 was observed in children with spina bifida than in controls (30.1 vs. 20.3%; OR = 1.69, 95% CI 1.02-2.83). High maternal body mass index (BMI) and glucose were significant risk factors for both H1 and H2 children, whereas low myo-inositol and zinc were risk factors for H2 but not for H1 children. Stepwise multiple logistic regression analysis showed that high maternal glucose and low myo-inositol are the main risk factors for H2 spina bifida children, whereas for H1 spina bifida children, maternal BMI was the main risk factor. Interestingly, H1 mothers (median 165.5 cm) showed a significantly lower body height than H2 mothers (median 169.1 cm; p = 0.003).
CONCLUSIONS: These data suggest that the child's PDGFRA promoter haplotype is differentially sensitive for periconceptional exposure to glucose, myo-inositol, and zinc in the risk of spina bifida.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19215021     DOI: 10.1002/bdra.20574

Source DB:  PubMed          Journal:  Birth Defects Res A Clin Mol Teratol        ISSN: 1542-0752


  6 in total

1.  Evaluation of 64 candidate single nucleotide polymorphisms as risk factors for neural tube defects in a large Irish study population.

Authors:  Tonia C Carter; Faith Pangilinan; James F Troendle; Anne M Molloy; Julia VanderMeer; Adam Mitchell; Peadar N Kirke; Mary R Conley; Barry Shane; John M Scott; Lawrence C Brody; James L Mills
Journal:  Am J Med Genet A       Date:  2010-12-10       Impact factor: 2.802

2.  A targeted sequencing panel identifies rare damaging variants in multiple genes in the cranial neural tube defect, anencephaly.

Authors:  M Ishida; T Cullup; C Boustred; C James; J Docker; C English; N Lench; A J Copp; G E Moore; N D E Greene; P Stanier
Journal:  Clin Genet       Date:  2018-02-11       Impact factor: 4.438

Review 3.  Spina Bifida: Pathogenesis, Mechanisms, and Genes in Mice and Humans.

Authors:  Siti W Mohd-Zin; Ahmed I Marwan; Mohamad K Abou Chaar; Azlina Ahmad-Annuar; Noraishah M Abdul-Aziz
Journal:  Scientifica (Cairo)       Date:  2017-02-13

Review 4.  Genetics of human neural tube defects.

Authors:  Nicholas D E Greene; Philip Stanier; Andrew J Copp
Journal:  Hum Mol Genet       Date:  2009-10-15       Impact factor: 6.150

5.  Copy number variations in 119 Chinese children with idiopathic short stature identified by the custom genome-wide microarray.

Authors:  Guorui Hu; Yanjie Fan; Lili Wang; Ru-En Yao; Xiaodong Huang; Yiping Shen; Yongguo Yu; Xuefan Gu
Journal:  Mol Cytogenet       Date:  2016-02-16       Impact factor: 2.009

6.  Folate metabolite profiling of different cell types and embryos suggests variation in folate one-carbon metabolism, including developmental changes in human embryonic brain.

Authors:  Kit-Yi Leung; Sandra C P De Castro; Filipe Cabreiro; Peter Gustavsson; Andrew J Copp; Nicholas D E Greene
Journal:  Mol Cell Biochem       Date:  2013-03-13       Impact factor: 3.396

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.